-
Cruise ship operator says Dutch to repatriate two ill passengers
-
India's Modi eyes win in opposition-held West Bengal
-
In Wales, UK Labour Party loses grip on storied heartland
-
Musk vs OpenAI trial enters second week
-
India's Modi faces key test as vote count underway
-
Japan PM says oil crisis has 'enormous impact' in Asia-Pacific
-
Badminton no.1 An brings 'fire' as South Korea win Uber Cup
-
Saka sparks Arsenal attack into life ahead of Atletico showdown
-
Atletico aim to show Alvarez their ambition in Arsenal semi
-
Seoul, Taipei hit records as Asian stocks track Wall St tech rally
-
Boeing faces civil trial over 737 MAX crash
-
Australian inquiry opens public hearings into Bondi Beach shooting
-
Iran warns of ceasefire violation as US plans to escort Hormuz ships
-
North Korean club to play rare football match in South
-
Pistons rout Magic to cap comeback, book NBA playoff clash with Cavaliers
-
Japan, Australia discuss energy, critical minerals
-
Village braces for closure of Spain's largest nuclear plant
-
GameStop makes $56 billion takeover bid for eBay
-
Ex-NY mayor Giuliani hospitalized in 'critical' condition: spokesman
-
Europe, Canada leaders hold Yerevan talks in Trump's shadow
-
'No pilgrims': regional war hushes Iraq's holy cities
-
Israel court extends detention of two Gaza flotilla activists
-
Massive search continues for two missing US soldiers in Morocco
-
Players keep up battle with tennis majors as they decry Roland Garros prize money
-
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
-
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business
-
Ameriwest Expands Bornite Property to Secure Broader Breccia Pipe Exploration Upside
-
Securitas Acquires CamVision to Expand Packaged and Advanced Security Solutions in Denmark
-
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
-
EB5 United Surpasses 800 I-526E Approvals in Post-RIA EB-5 Landscape
-
Pistons rout Magic to complete comeback, advance in NBA playoffs
-
Trump says US and Iran in 'positive' talks, unveils plan to escort Hormuz ships
-
Talisman Endrick fires resurgent Lyon into third in France
-
Verstappen laments spin and struggle for pace in Miami
-
Teen Antonelli wins again in Miami to extend title race lead
-
Ferrari's Leclerc admits he threw away Miami podium finish
-
Cristian Chivu, a winner with Inter on the pitch and in the dugout
-
Key players from Inter Milan's Serie A title triumph
-
No.4 Young cruises to PGA title at Doral
-
Vinicius double delays Barca title as Real Madrid down Espanyol
-
Inter Milan win Italian title for third time in six seasons
-
Spurs solved mental frailty to boost survival bid: De Zerbi
-
Miami champ Antonelli shrugs off success, vows 'back to work'
-
Man Utd beat Liverpool, Spurs climb out of relegation zone
-
Spurs out of relegation zone after vital win at Villa
-
No.1 Korda cruises to LPGA Mexico crown
-
Thompson-Herah shines at world relays, Tebogo helps Botswana to win
-
Three die on Atlantic cruise ship from suspected hantavirus: WHO
-
Germany's Merz says not 'giving up on working with Donald Trump'
-
Mercedes' Kimi Antonelli wins Miami Grand Prix
CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 8, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2025, after the stock market closes on Wednesday, August 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1727552&tp_key=38f7de0673. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, August 20, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13754956.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
P.Hernandez--AT